Conference Coverage
Gene test predicts metastasis of sentinel node-negative melanomas
Major finding: Metastasis-free survival was 31% and overall survival was 49% at 5 years in the 64 patients who had negative sentinel node lymph...
DENVER – A 134-patient study of patients with stage I, II, or III cutaneous melanoma found that the DecisionDx-Melanoma test was useful for identifying a high-risk group of patients with negative sentinel lymph node biopsy results.
In a video interview, Dr. Pedram Gerami of the department of dermatology and director of melanoma research at the Northwestern University Skin Cancer Institute, Chicago, explains the best uses for the test and its patient management advantages.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel .
On Twitter @naseemmiller